Oncolytic viruses constitute a promising new therapeutic approach for treatment of cancer. These viruses selectively kill tumor cells without harming normal ones; with the added bonus of stimulating the patient’s immune response
- Because immunogenicity includes both adaptive and innate immune responses in oncolytic viral therapy, Viracor offers multiple assays for immunogenicity analysis including anti-drug antibodies (ADA), and neutralization antibody (NAb)detection against the vector .
- Viracor can also custom develop biodistribution and viral shedding assays by qPCR, for clinical trial studies; including quantitative analysis for outcome measures, These studies can be valuable for assessing the potential for transmission of virus/vaccine from infected/vaccinated subjects to unvaccinated/uninfected individuals.
- RCR/RCL detection/quantification
- Platforms for gene therapy studies (Flow Cytometry, qPCR, ELISA, ELISpot)